ASCO Prostate Cancer Symposium 2007:15 abstracts with comments

نویسنده

  • Kees DeJong
چکیده

1 = number of abstract – I’ll ask to have CRP added to my monthly bloodtest 2 – I’ll ask to have LDH added to my monthly bloodtest 3 and 4 – Taxotere (docetaxel) + estramustine (3x280 mg/day) better than Taxotere alone 5 – same as 3 and 4, but 3x140 mg/day estramustine equally effective as 3x280 mg, and less toxic 6 – Thalidomide + bevacizumab (Avastin) + Taxotere: works! 7 – Taxotere + Carboplatin works after Taxotere alone stopped working 8 – weekly Taxotere + capecitabine (Xeloda + oral drug) is effective and well-tolerated 9 – Carboplatin + Avastin + Xeloda worked in one patient who did not respond to Taxotere alone 10 – Satraplatin + prednisone is barely better than placebo + prednisone: “at 12 mos, 16% (S+P) and 7% (P) had not progressed” 11 – Decadron (dexamethasone) has synenergy with Taxotere, at least in the Petri dish. I don’t take daily prednisone while on chemo, but 2x0.5 mg Decadron. Should I take more? 12 – biweekly Taxotere + 800 mg Celebrex/day works 13 – some patients, not responding to Taxotere, will respond to four estradiol patches – with comments by Dr. Charles Myers (3/3/07) 14 – 8 of 74 patients on Taxotere + estramustine had a PSA ‘flare-up’; did not impact survival 13, 14 & 15: androgen receptor and androgens continue to play a role after patients become hormonerefractory!

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

2007 EORTC-NCI-ASCO Annual Meeting: Molecular Markers in Cancer

The recent EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer' was held on 15-17 November 2007 in Brussels, Belgium. It was the largest meeting to date and marked the first year in which the American Association of Clinical Oncology (ASCO) joined in the efforts of the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI) in organiz...

متن کامل

Identification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.

Pancreatic cancer remains a significant cause of morbidity and mortality. While increasing treatment options have improved outcomes for many patients, they have also complicated decision-making for treatment. Unfortunately, most patients with pancreatic cancer die from their disease. Prognostic and predictive markers could play a role to improve treatment by identifying patients who may or may ...

متن کامل

First-line treatment for advanced pancreatic cancer.

Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options. The authors summarize four abstracts (#148, #233, #158, #291) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused on novel agents for metastatic pancreatic cancer.

متن کامل

Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.

© 2 0 1 0 T H E A U T H O R S B J U I N T E R N A T I O N A L © 2 0 1 0 B J U I N T E R N A T I O N A L 2 2 7 2006 , Edinburgh, Scotland: National Cancer Institute, 2009. Available at: http:/ /seer.cancer.gov/csr/1975_2006/. Based on November 2008 SEER data submission, posted to the SEER web site 2 Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe ...

متن کامل

The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.

Pancreatic cancer is sometimes called a "silent killer" because it is often not diagnosed until it is advanced. It remains the fourth leading cause of cancer-related death in the United States. Gemcitabine has been the front line therapy for advanced pancreatic cancer over the past 10 years. Over this time period, survival benefit has not been able to improve substantially from studies of gemci...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2007